Medical Device Reprocessing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The medical device reprocessing market size is expected to grow from USD 5.09 billion in 2025 to USD 5.87 billion in 2026 and is forecast to reach USD 11.97 billion by 2031 at 15.30% CAGR over 2026-2031. This report is Segmented by Device Type (Critical, Semi-Critical, Non-Critical), Offering Type (Reprocessed Devices, Reprocessing Support and Services), Application (Cardiology, Gastroenterology, Orthopedics, Gynecology, General Surgery), End User (Hospitals, Ascs, Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts are in Value (USD).

Global Medical Device Reprocessing Market Trends and Insights

Hospital Supply Cost Containment and Recurring Per-Procedure Savings

In 2025, AMDR member companies sold 39,387,336 reprocessed single-use devices to 11,458 healthcare facilities across 18 countries, generating USD 495.5 million in documented savings for hospitals. AMDR highlighted that if all US hospitals reprocessed at the rate of the top 10% of adopters, the annual savings opportunity could reach USD 2.43 billion. This gap emphasizes the increasing focus on the medical device reprocessing market within major health systems, where purchasing decisions are evaluated against operating margins, liquidity, and supply efficiency. Financial stakes are also evident in the Veterans Health Administration debate, where AMDR estimated that current restrictions left USD 167 million in annual taxpayer savings unrealized in 2025. With device-level savings often reaching 40 to 60% against OEM list prices, the medical device reprocessing market aligns well with procurement strategies prioritizing repeatable savings at the procedure level.

Sustainability Reporting Pressure on Health Systems

Sustainability goals are becoming a key factor in the medical device reprocessing market as hospital systems face increasing pressure to demonstrate progress on Scope 3 emissions. Reprocessed devices are identified as a rare supply-chain action that reduces both costs and emissions, offering procurement teams a clear strategy to balance cost and climate objectives. In fiscal 2025, Cardinal Health's Sustainable Technologies business collected 21.6 million single-use devices, diverting 6.6 million pounds of waste from landfills, and avoiding 1,900 metric tons of carbon dioxide equivalent emissions. European policy movements further support this trend, with Denmark authorizing commercial single-use device reprocessing in January 2025 and France initiating a hospital reprocessing experiment in September 2025. Procurement rules increasingly recognize environmental performance as integral to supplier value in the medical device reprocessing market.

OEM Contracting Tactics and Device Lock-In

OEM contracting practices continue to limit the medical device reprocessing market, particularly in high-value categories influenced by proprietary systems. In May 2025, a jury ruled against Johnson & Johnson's Biosense Webster unit, and a permanent injunction in September 2025 prohibited actions such as linking clinical support to new device purchases, disabling reprocessed devices with embedded chips, and withholding used devices essential for reprocessing. The damages totaled USD 442 million after being tripled, highlighting the commercial significance of the issue. However, softer resistance persists, including software lockouts, reduced staff training, and restrictive contract structures that hinder hospital transitions. Federal agencies addressed the issue in 2025 by launching an anonymous reporting portal for anticompetitive practices in the medical device sector. While access has improved in some product categories, inconsistent procurement freedom continues to slow progress in other areas.

Other drivers and restraints analyzed in the detailed report include:

• AI-Enabled Tray and Cycle Tracking Improves Compliance
• Expanded OEM Reprocessed-Device Portfolios
• Clinical Trust Barriers for Reprocessed High-Acuity Devices

Segment Analysis

In 2025, Semi-Critical Devices dominated the medical device reprocessing market, accounting for 44.45% of the segment's revenue. This stronghold is attributed to established reprocessing pathways for items like flexible endoscopes and respiratory therapy circuits. Many hospital sterile supply departments have standardized high-level disinfection protocols for these devices. Clinicians are more accepting of these categories due to hospitals' extensive operating experience and clear handling routines. Non-Critical Devices, which include electrodes and pulse oximeter sensors, made up the remaining share. While reprocessing is accepted for these items, the savings per unit are smaller due to their lower original acquisition costs.

Critical Devices are set to experience a robust growth rate of 16.45% CAGR through 2031, making them the fastest-growing category in the medical device reprocessing market. This surge is linked to the growing acceptance of reprocessed electrophysiology catheters and laparoscopic instruments in the U.S., alongside an expansion of eligibility under EU MDR frameworks in Europe. Furthermore, a September 2025 injunction against Biosense Webster has eased access conditions in a previously constrained device class. While Semi-Critical Devices currently dominate the market share, the trend indicates a shift in value creation towards critical devices. This shift is bolstered by the advent of digital audit trails and validation systems, simplifying complex reprocessing programs for clinical and regulatory reviews.

In 2025, Reprocessed Medical Devices made up 62.55% of the offering-type revenue, underscoring the market's reliance on physical device throughput over service-only contracts. High demand in fields like gastroenterology and cardiology drives this segment, as hospitals frequently replace these items and can directly measure savings. This dynamic fosters a consistent procurement rhythm across extensive hospital networks. It also highlights that buyers typically enter the market through specific device categories before branching out into broader partnerships.

Reprocessing Support and Services is on track to grow at a robust 16.77% CAGR through 2031, positioning it as the more dynamic segment of the medical device reprocessing market. Major health systems are increasingly seeking integrated solutions, desiring collection logistics, validation support, and tracking software as a cohesive program rather than standalone purchases. Cardinal Health exemplified this trend in 2026, merging ValueLink analytics with its Sustainable Technologies offering to enhance supply-chain efficiency for large health systems. A 2025 life cycle study emphasized collection logistics and sterilization design as key areas for environmental enhancement, bolstering the case for service-led differentiation. As price competition tightens device margins, operators demonstrating savings, compliance, and environmental performance as a bundled service stand to capture more value in the market.

Complete Report Scope:

• By Device Type
  • Critical Devices
  • Semi-Critical Devices
  • Non-Critical Devices
• By Offering Type
  • Reprocessed Medical Devices
  • Reprocessing Support and Services
• By Application
  • Cardiology
  • Gastroenterology
  • Orthopedics
  • Gynecology
  • General Surgery
  • Other Applications
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In 2025, North America accounted for 42.99% of global revenue in the medical device reprocessing market, securing the largest regional share. This dominance stems from extensive commercial adoption, strong Group Purchasing Organization frameworks, and a regulatory environment holding third-party reprocessors to standards similar to original manufacturers. The US EPA's March 2026 proposal to revisit parts of the 2024 ethylene oxide rule highlighted the direct impact of sterilization policies on regional supply capacity.

Europe remains a critical regulatory hub for the medical device reprocessing market, with adoption heavily influenced by country-specific legal frameworks and hospital procurement policies. In 2025, France initiated a hospital trial for reprocessing single-use devices, including electrophysiology catheters, under Décret n° 2025-895. A public policy review in France estimated 35% to 59% savings per reprocessed device, supporting broader hospital participation if the pilot expands. Denmark's approval of commercial reprocessing for single-use devices in January 2025 signaled a shift toward sustainability-focused health systems. EU MDR Article 17 and ISO 13485:2016 continue to shape market entry, favoring operators with validated quality systems and strong documentation capabilities.

Asia-Pacific is projected to grow at a 15.96% CAGR through 2031, making it the fastest-growing region in the medical device reprocessing market. Growth is driven by rising surgical volumes, hospital infrastructure investments, and improved procurement practices in countries like China, India, South Korea, Australia, and Japan. Cardinal Health's remanufacturing facility in Beresfield, Newcastle, Australia, set for full operation in FY2027, marks a significant international expansion. While South Korea and Japan offer regulatory maturity, China and India present large-scale opportunities as compliance frameworks strengthen and hospital purchasing systems formalize.

List of Companies Covered in this Report:

• Arjo AB
• Avante Health Solutions
• B. Braun
• Cardinal Health
• Getinge
• Innovative Health, LLC
• Johnson & Johnson
• Konoike Co., Ltd.
• Medline Industries
• MedSalv Australia Pty Ltd
• Medtronic
• MidWest Reprocessing Center
• NEScientific
• Olympus
• ReNu Medical, Inc.
• SteriPro Canada Inc.
• STERIS
• Stryker
• SureTek Medical
• Vanguard

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support